Insmed (NASDAQ:INSM) Announces Quarterly Earnings Results

Insmed (NASDAQ:INSM) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15), Zacks reports. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed updated its FY 2025 guidance to EPS.

Insmed Stock Down 3.0 %

Shares of INSM stock traded down $2.55 during trading hours on Friday, hitting $81.06. 2,722,240 shares of the company’s stock traded hands, compared to its average volume of 1,686,738. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The stock’s fifty day simple moving average is $74.29 and its two-hundred day simple moving average is $73.59. Insmed has a 12-month low of $21.92 and a 12-month high of $84.91. The stock has a market cap of $14.50 billion, a price-to-earnings ratio of -14.50 and a beta of 1.11.

Analysts Set New Price Targets

Several research firms have weighed in on INSM. Truist Financial boosted their price target on shares of Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday. Stifel Nicolaus lowered their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research note on Wednesday. Morgan Stanley increased their price target on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Finally, JPMorgan Chase & Co. raised their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, Insmed has an average rating of “Moderate Buy” and an average target price of $91.00.

Insider Buying and Selling

In other Insmed news, CFO Sara Bonstein sold 1,066 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.72, for a total transaction of $67,925.52. Following the sale, the chief financial officer now directly owns 118,863 shares in the company, valued at approximately $7,573,950.36. This trade represents a 0.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00. Following the completion of the transaction, the chief executive officer now owns 384,960 shares of the company’s stock, valued at $26,885,606.40. This represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 532,207 shares of company stock worth $41,400,465 in the last 90 days. Insiders own 4.60% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.